Sanofi Not "Desperate" To Improve Ambien Label In Face Of Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Newcomers to the sleep agent category are benchmarked against Ambien, Exec VP Pharmaceutical Operations Spek tells analysts. Ambien's closest competitor is likely to be Ambien CR, Sanofi says.
You may also be interested in...
Lunesta Has "Encouraging" Debut, Sepracor Says
For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.
Lunesta Has "Encouraging" Debut, Sepracor Says
For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.
Sanofi-Aventis’ Ambien CR “Approvable” At FDA
Sanofi-Aventis' controlled-release formulation of its insomnia agent zolpidem, Ambien CR, received an FDA "approvable" letter, the company announced April 11